The estimated Net Worth of Teresa L. Kline is at least $213 Tausend dollars as of 16 March 2020. Ms. Kline owns over 1,000 units of Intersect ENT Inc stock worth over $50,267 and over the last 7 years she sold XENT stock worth over $0. In addition, she makes $162,420 as Independent Director at Intersect ENT Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Kline XENT stock SEC Form 4 insiders trading
Teresa has made over 1 trades of the Intersect ENT Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she bought 1,000 units of XENT stock worth $142,630 on 16 March 2020.
The largest trade she's ever made was buying 1,000 units of Intersect ENT Inc stock on 16 March 2020 worth over $142,630. On average, Teresa trades about 50 units every 0 days since 2017. As of 16 March 2020 she still owns at least 1,780 units of Intersect ENT Inc stock.
You can see the complete history of Ms. Kline stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Teresa Kline biography
Teresa L. Kline is the Independent Director of INTERSECT ENT, INC.. She has served as a member of our Board of Directors since August 2017. From November 2016 through June 2019, Ms. Kline served as the Executive Vice President of Henry Ford Health System, or HFHS, a health care provider, and the President and Chief Executive Officer of Health Alliance Plan, a health insurance company and subsidiary of HFHS. From July 2014 to November 2016, Ms. Kline provided health care consulting services. Ms. Kline served as Senior Vice President and Chief Health Care Management Officer of Health Care Service Corporation, a health insurance company, from March 2010 to March 2014. Since November 2019, Ms. Kline has served as a member of the board of directors of Amedisys, a home health and hospice company. Since August 2017, Ms. Kline has served on the board of directors of SaVida Health, an opioid use disorder treatment company. Since April 2016, Ms. Kline has served as a member of the board of directors of LaunchPoint Ventures LLC, a health payment integrity company. Since October 2015, Ms. Kline has also served as a member of the board of directors of Presbyterian Health Plan, Inc., a health insurer, and as Vice Chairman since January 2017.
What is the salary of Teresa Kline?
As the Independent Director of Intersect ENT Inc, the total compensation of Teresa Kline at Intersect ENT Inc is $162,420. There are 10 executives at Intersect ENT Inc getting paid more, with Thomas West having the highest compensation of $7,206,100.
How old is Teresa Kline?
Teresa Kline is 61, she's been the Independent Director of Intersect ENT Inc since 2017. There are 4 older and 8 younger executives at Intersect ENT Inc. The oldest executive at Intersect ENT Inc is Frederic Moll, 68, who is the Independent Director.
What's Teresa Kline's mailing address?
Teresa's mailing address filed with the SEC is OWENS & MINOR, INC., 9120 LOCKWOOD BLVD, MECHANICSVILLE, VA, 23116.
Insiders trading at Intersect ENT Inc
Over the last 10 years, insiders at Intersect ENT Inc have traded over $22,664,783 worth of Intersect ENT Inc stock and bought 58,846 units worth $713,631 . The most active insiders traders include Rick D Anderson, Lisa D Earnhardt und W Anthony Vernon. On average, Intersect ENT Inc executives and independent directors trade stock every 18 days with the average trade being worth of $344,556. The most recent stock trade was executed by Frederic H Moll on 19 January 2021, trading 12,500 units of XENT stock currently worth $9,000.
What does Intersect ENT Inc do?
Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company's PROPEL® and SINUVA® sinus implants and extend its geographic reach.
What does Intersect ENT Inc's logo look like?
Complete history of Ms. Kline stock trades at Amedisys, Intersect ENT Inc und Owens & Minor
Intersect ENT Inc executives and stock owners
Intersect ENT Inc executives and other stock owners filed with the SEC include:
-
Thomas West,
President, Chief Executive Officer, Director -
Kieran Gallahue,
Non-Executive Chairman of the Board -
Richard Meier,
Chief Financial Officer, Executive Vice President -
Christine Kowalski,
Chief Operating Officer, Executive Vice President -
Gwen Carscadden,
Chief People Officer -
Thomas A. West,
Pres, CEO & Director -
Richard A. Meier,
Exec. VP & CFO -
Cynthia Lucchese,
Independent Director -
Dana Mead,
Independent Director -
William Vernon,
Independent Director -
Teresa Kline,
Independent Director -
Frederic Moll,
Independent Director -
Patrick A. Broderick,
Exec. VP, Gen. Counsel & Corp. Sec. -
Reyna M. Fernandez,
Chief Human Resource Officer -
Drake R. Parker,
Advisor of Strategic Initiatives -
Jeryl L Hilleman,
Chief Financial Officer -
Lisa D Earnhardt,
-
Casey M Tansey,
Director -
Amy Wolbeck,
See Remarks -
Susan P Stimson,
Vice President, Marketing -
Richard E Kaufman,
See Remarks -
Drake R. Parker,
Chief Business Officer -
David Aaron Lehman,
EVP & General Counsel -
Neil A Hattangadi,
-
Robert H Jr Binney,
Chief Commercial Officer -
Rick D Anderson,
Director -
Sciences Ii L P Pinto Techn...,
-
Clercq Casper L. De,
Director -
Sciences Ii L P Pinto Techn...,
-
Perkins Caufield & Byers Xi...,
-
James Stambaugh,
VP, Clinical and Reimbursement -
Chas Mc Khann,
Chief Commercial Officer -
Mark J Fletcher,
Director -
Management Group Ix, L.L.C....,
-
Venture Partners Xi, Lp Nor...,
-
W Anthony Vernon,
-
Reyna M Fernandez,
Chief Human Resource Officer -
Patrick A Broderick,
EVP, GC & Corporate Secretary -
Elisabeth Sandoval,